Compare BEN & HOLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BEN | HOLX |
|---|---|---|
| Founded | 1947 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Electronics |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.5B | 16.6B |
| IPO Year | 2013 | 1995 |
| Metric | BEN | HOLX |
|---|---|---|
| Price | $24.00 | $75.60 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 9 | 13 |
| Target Price | $25.89 | ★ $77.89 |
| AVG Volume (30 Days) | ★ 4.4M | 2.8M |
| Earning Date | 05-01-2026 | 04-30-2026 |
| Dividend Yield | ★ 5.63% | N/A |
| EPS Growth | ★ 7.06 | N/A |
| EPS | 0.46 | ★ 0.79 |
| Revenue | ★ $5,774,500,000.00 | $4,100,500,000.00 |
| Revenue This Year | N/A | $4.74 |
| Revenue Next Year | $5.76 | $5.03 |
| P/E Ratio | ★ $51.04 | $95.47 |
| Revenue Growth | N/A | ★ 1.74 |
| 52 Week Low | $16.25 | $51.90 |
| 52 Week High | $28.32 | $75.75 |
| Indicator | BEN | HOLX |
|---|---|---|
| Relative Strength Index (RSI) | 37.87 | 60.36 |
| Support Level | $22.68 | $75.10 |
| Resistance Level | $25.52 | N/A |
| Average True Range (ATR) | 0.73 | 0.23 |
| MACD | -0.22 | -0.01 |
| Stochastic Oscillator | 16.55 | 78.00 |
Franklin Resources provides investment services for individual and institutional investors. At the end of July 2025, Franklin had $1.617 trillion in managed assets, composed primarily of equity (41%), fixed-income (27%), multi-asset/balanced (11%) funds, alternatives (16%) and money market funds (5%). Distribution tends to be weighted between retail investors (56% of AUM) and institutional accounts (41%), with high-net-worth clients accounting for the remainder. Franklin is one of the more global of the US-based asset managers we cover, with 31% of its assets under management invested in global/international strategies and just as much sourced from clients domiciled outside the United States.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.